Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 16/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883728 | 0.85 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6806574 | 0.83 | HSD17B1 (0.65) | MCHR1HSD17B1HSD17B2 | |
| SCHEMBL4880423 | 0.82 | HDAC3 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4090142 | 0.80 | HSD17B1 (0.58) | MCHR1HSD17B1HSD17B2 | |
| SCHEMBL7376311 | 0.79 | HSD17B1 (0.57) | MCHR1HSD17B1HSD17B2 | |
| SCHEMBL4881186 | 0.77 | HDAC3 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5582735 | 0.77 | CA1 (0.67) | MCHR1HSD17B1HSD17B2 | |
| SCHEMBL4883456 | 0.77 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5582630 | 0.76 | MCHR1 (0.56) | MCHR1HSD17B1HSD17B2 | |
| SCHEMBL17213443 | 0.76 | HPGD (0.62) | MCHR1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1819669-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006063294-A2 | NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | HDAC3 11/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.